Algos MorphiDex Has Dec. 31, 2001 Deadline For FDA Approval In Endo Deal
Algos has an upcoming Dec. 13 meeting with FDA regarding the future of its cancer pain treatment MorphiDex that could influence the value of the company's proposed merger with Endo Pharmaceuticals.
You may also be interested in...
Launch of Endo Pharmaceuticals' Lidoderm patch for post-herpetic neuralgia pain is pending completion of manufacturing scale-up for commercial distribution.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials